A Dose Of Reality With Charles Spence podcast

1
Chris Leamon, CSO at Fusion Therapeutics - Acquisition of Endocyte, Career reflections and more 37:25

vor 12 Tagen37:25

37:25

In this episode, I talked with Dr. Chris Leamon, Chief Scientific Officer at Fusion Pharmaceuticals, where he shares his journey in the biotech industry, discussing his early influences, the founding of Endocyte, and . He also discusses the challenges faced in drug development, the importance of leadership during workforce reductions, and the lessons learned from trial failures. Chris emphasizes the significance of execution, continuous learning, and building a strong team in the biotech field. Here's what you're in: What made Chris pursue a career in oncology? Why did Chris join Fusion Pharmaceuticals? What are big mistakes companies are still making today? Timestamps: 02:41 Early Influences and Career Beginnings 06:43 Transitioning into Radiotherapeutics Field 13:36 The Process of Pivoting Trials 16:50 Dealing with Workforce Reduction 20:53 Joining Fusion Pharmaceuticals and Future Aspirations 24:36 Insights on Trial Failures and Learning Experiences 29:17 Hiring Practices and Building a Strong Team 34:11 Advice for Aspiring Biotech Professionals About Chris Dr. Chris Leamon is the Chief Scientific Officer at Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company that specializes in developing targeted alpha therapeutics for the treatment of cancer. He is also a scientific co-founder of Endocyte, the company that developed Pluvicto, and he has been an executive associated with two biotech acquisitions over the past six years: Endocyte (purchased by Novartis in Dec. 2018) and Fusion Pharmaceuticals (purchased by Astra Zeneca in June, 2024). Dr. Leamon earned his PhD in Biochemistry at Purdue University. Connect with Chris LinkedIn: https://www.linkedin.com/in/chris-leamon-393639b/ Company Website: https://fusionpharma.com/ About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.…

1
Dawn Rubel, Dawn Rubel, President R&D at NexEos Bio - Eosinophilic Esophagitis, Purposeful Leadership and more 34:39

vor 19 Tagen34:39

34:39

In this episode, I talked with Dawn Rubel, President of R&D at NexEos Bio, where she shares her career journey from a scientific technical writer to a leadership role in biotech. She discusses her experiences at Immunomedics, the development of Trodelvy, and her transition to NexEos Bio, where she focuses on eosinophilic inflammation. Dawn emphasizes the importance of teamwork, hiring the right people, and learning from failures in clinical trials. She also provides valuable advice for aspiring leaders and highlights the significance of passion in one's work. Here's what you're in: Why did Dawn move into quality, regulatory, and leadership instead of staying in technical writing? What is the biggest lesson she learned from her career journey? Who does Nexeos Bio aim to help, and what is the company’s approach? Timestamps 01:52 Dawn's Career Journey 05:20 Immunomedics and Troldevy 08:05 Joining Nexeos Bio 11:47 Challenges and Opportunities at NexEos Bio 15:09 Failures and Lessons in Clinical Trials 22:10 Insights About Hiring and Leadership 31:25 Advice for Aspiring Leaders About Dawn Dawn Rubel is the President of Research and Development at NexEos Bio, a privately held medical diagnostics and therapeutics company focused on developing innovative technologies for eosinophil-mediated diseases. Dawn has successful leadership experience in Biotech, Pharma, Medical Device from global multibillion-dollar corporations (Pfizer, Arthrex) to small biotechs (Immunomedics, NexEos Bio). She held leadership roles in safety, quality, & regulatory in her previous companies. She earned an MBA in Fairleigh Dickinson University and she did her Graduate Studies in Industrial Pharmacy, Pharmaceutics and Drug Design in Long Island University. Connect with Dawn LinkedIn: https://www.linkedin.com/in/dawn-rubel/ Company Website: https://www.nexeosbio.com/ About Me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.…

1
Örn Almarsson, Co-Founder of Axelyf - Modernas SpikeVax, the challenge of mRNA delivery and Salmon's inspiration behind Axelyf? 35:35

vor 26 Tagen35:35

35:35

In this episode, I talked with Orn Almarsson, co-founder of Axelyf, where he shared his journey from Iceland to becoming a prominent figure in the biotechnology industry. He discussed his experiences at Moderna and the development of the mRNA COVID vaccine, Spikevax. He reflects on the challenges faced in drug development, the importance of mentorship, and the founding of his own company, Axelyf, which focuses on anti-inflammatory solutions. Orn emphasizes the significance of hiring passionate individuals, the need for feedback in recruitment, and the value of networking and mentorship for career success. Here's what you're in: What success has he worked on Spikevax mRNA COVID vaccine, and what has he learned from it? What is Axelyf and its mission? What qualities of an individual is important when it comes to hiring? Timestamps: 02:06 From Iceland to California 05:55 Joining Merck and Early Experiences 07:44 The Moderna Journey and Spikevax 15:26 Founding Axelyf and Its Mission 22:39 Industry Observations and Hiring Insights 32:14 Advice for Aspiring Professionals About Orn Orn Almarsson, co-founder of Axelyf, an Icelandic biotechnology start-up focusing on designing and developing medicines for inflammatory and autoimmune conditions. Orn is a pharmaceutical scientist turned executive with 30 years in the industry and has worked with multiple products including the Covid vaccine, Spikevax at Moderna. He has a PhD in Bioorganic Chemistry from UC Santa Barbara, originally from Iceland but now lives in Massachusetts. Connect with Orn LinkedIn: https://www.linkedin.com/in/%C3%B6rn-almarsson-9511b86/ Company Website: https://www.axelyf.com/ About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.…

1
Leila Jaafar, CEO at Nuclidium - from PhD to Radiotherapy CEO 31:52

vor 5 weeks31:52

31:52

In this episode, I talked with Dr. Leila Jaffar, CEO of Nuclidium, where she shares her journey from a childhood influenced by her father's passion for science to becoming a leader in the biotech industry. She discusses the challenges she faced during her career, including personal and professional, and her transition from academia to industry. Leila elaborates on the mission of Nuclidium, focusing on the development of copper-based diagnostics and therapeutics for oncology. She also emphasizes the importance of company culture, the impact of every team member, and the lessons learned in leadership and hiring. Here's what you're in: What is the goal with Nuclidium? How can networking becomes crucial for career advancement? Why did you decide to go down the founder route? Timestamps: 02:08 Journey into Life Sciences 04:26 Dealing With Career's Lowest Point 09:31 Getting A Job After Finishing PhD 11:09 Founding of her Own Company 14:37 Nuclidium and What Sets It Apart 21:55 Why Join Nuclidium - What is its Culture? 24:22 Lessons Learned Through Hiring and Managing People 27:38 Quickfire Questions About Leila Dr. Leila Jaafar, CEO of Nuclidium, a clinical-stage radiopharmaceutical working on copper-based diagnostics and therapeutics. Dr. Leila is also the co-founder of LinaThera, which is partnered with Nuclidium and focuses on the production of medical radionuclides. Prior to joining Nuclidium, she was the CEO of Swiss Nuclides for 5 years and Program Manager at Areva for 6 years. Outside of her professional role, she plays the violin and loves to read in her free time. Connect with Leila LinkedIn: https://www.linkedin.com/in/leila-jaafar-605642130/ Company Website: https://nuclidium.com/ About Me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.…

1
CMO at Indaptus, Roger Waltzman, on Dangers of Pushing Uncertain Data into Phase III 30:30

vor 6 weeks30:30

30:30

In this episode, I talked with Roger Waltzman, Chief Medical Officer at Indaptus Therapeutics, discussing his career, overview of Indaptus, the development of Indaptus’ lead candidate, and the challenges of cancer treatment. We explore the benefits of a multi-targeted approach in immunotherapy, the story, and the lessons he learned from the failed Phase 3 trial of Vadimezan. Roger also serves as a Board of a non-profit organization called GoDocGo which provides low-cost cervical cancer screening in low-middle income countries and its impact. Here's what you're in: What are other lessons from the Vadimezan Phase III failure? What is unique about Indaptus? Why are so few companies focused on multi-targets and instead focus mostly on targeted therapy? Timestamps: 00:38 Introduction and Career Background 02:16 About Indaptus' Broad Immune Stimulant 05:08 Advantages of a Broad, Multi-Targeted Approach 10:08 Why Companies Don't Do Broad, Multi-Targeted Approach 13:44 Vadimezan and its Science 16:06 Learning Experiences from Clinical Trials of Vadimezan 21:58 Insights About Rushing the Trials into Phase III 26:53 GoDocGo: Inexpensive Cervical Cancer Screening About Roger Roger Waltzman is a Chief Medical Officer at Indaptus Therapeutics, where he leads the Phase 1a/b immuno-oncology program. Indaptus develops anti-cancer and anti-viral immunotherapy products, with its lead candidate, Decoy20, currently in Phase 1 trials. Indaptus' proprietary platform utilizes non-pathogenic bacteria and has patent protection in 32 countries. Before Indaptus, Dr. Waltzman held CMO roles at Molecular Templates and RegenX (now Inspirna), and he spent nine years at Novartis, where he led clinical development teams, including the Jakavi collaboration. Dr. Waltzman also holds an MD from Brown and an MBA from Columbia. He serves as a Board of a non-profit organization called GoDocGo which provides low-cost cervical cancer screening. Connect with Roger LinkedIn: https://www.linkedin.com/in/roger-waltzman-021bb91/ Company Website: https://indaptusrx.com/ Organization: https://www.godocgo.org/ About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.…

1
Gertjan Bartlema, Co-founder Populus Bio and CEO of Immodulon Therapeutics. on Innovation in Biotechs 38:02

vor 7 weeks38:02

38:02

In this episode, I spoke with Gertjan Bartlema, the co-founder Populus Bio and CEO of Immodulon Therapeutics. Over 20 years in big pharma at Celgene/Amgen and then moved into the fast pace world of biotech. From here, he has been challenging the status quo and asking the question “Is our current drug development approaches sustainable?”. Gertjan highlights the need for better clinical trial designs and the importance of making objective decisions based on data. He also offers valuable insights for aspiring executives on leadership and team dynamics. Here's what you're in: How many drugs fail end-points due to Bad Leadership? Why does Gertjan believe sequential and traditional drug Development can kill innovation within Drug Development?. What advice does Gertjan give to those wanting to become a CEO? Timestamps: 02:53 The Abraxane Course Correction 06:03 Gertjan’s Journey into Life Sciences 10:40 Leaving Celgene and New Ventures 15:50 Bayesian Statistics in Clinical Studies 19:27 Mistakes Companies Are Still Making Today 25:38 The Ambitious People 35:46 Advice for Aspiring Executives About Gertjan Gertjan Bartlemais co-founder of Populus Bio and current CEO of Immodulon Therapeutics which is running cancer trials focusing on a broad spectrum immunomodulator. He is a global biotech executive with extensive experience in EU and US operational roles and he is a member of founding Celgene EMEA management establishing EU footprint and launching Revlimid. Prior to joining Immodulon, he was the Chief Business Officer of Vico Therapeutics, and spent 12 years with Celgene, where he led the trial of Revlimid. Gertjan holds MSc in Economics from Maastricht University. Connect with Gertjan LinkedIn: https://www.linkedin.com/in/gertjan-bartlema/ Populus Bio: https://populusbio.com/ Immodulon Therapeutics: https://www.immodulon.com/ About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.…

1
The 3 Most Common Rejection Reasons During an Interview 18:25

vor 9 weeks18:25

18:25

In this episode, I discuss the three most common reasons hiring managers reject candidates, focusing on aspects that are often within the candidate's control. I highlight the importance of cultural fit, alignment of interests, and clarity in communication during interviews. I give tips to improve your interview performance and avoid common pitfalls that lead to rejection. Here's what you're in: How cultural fit can be influenced by candidate behavior? How using vague terms like 'strategy' can lead to misunderstandings? Why building rapport with interviewers is crucial for success? Timestamps: 01:09 Background Story 03:37 Not a Good Cultural Fit 07:29 Candidates Going To Get Bored/ Not Hands-on Enough 12:01 Not Giving Straight to the Point Answers 16:52 Summary About Me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/…

1
The Most Common Hiring Mistakes by Hiring Managers in 2024 ft. Caroline Vermeulen, Eminence 40:47

vor 11 weeks40:47

40:47

In this episode, I talked with Caroline Vermeulen, Recruitment & HR at Eminence, as she discussed into the details of the hiring process, highlighting the value of putting candidates first. She gave insights on common mistakes in recruiting, the importance of authenticity in communication, and the relationship between hiring managers and recruiters. Caroline and I also shared stories of both our best and worst hiring experiences, emphasizing out the need for clear expectations and good communication. Our conversation wraps up with a round of quickfire questions, providing more tips on recruitment best practices. Here's what you're in: What are the most common hiring mistakes and how does that affect things later on? How long should a CV be? How long should an interview be? To give or not to give controversial feedback to candidates? Timestamps: 01:50 Introduction and Career Background 03:16 Caroline's New Mission: candidate-first 06:19 Common Mistakes in Recruitment Processes 09:31 Importance of Authenticity in Communication 11:11 Communication Strategies with Hiring Managers 16:35 Building a Smooth and Clean Recruitment Process 22:43 Best and Worst Experience in Recruitment 34:00 Quickfire Questions and Insights About Caroline Caroline Vermeulen is a Recruitment & HR at Eminence. She has an educational background of Bsc in Life sciences/Biotechnology, has over a decade of experience in the industry, including early-phase trials for generics, cell and gene therapies, immunotherapies, and pain medications, and has helped over a thousand candidates find jobs as a recruiter. Transitioning from agency to corporate recruitment, she faced challenges due to the complexities of corporate structures and the challenges in communication. Now, she is excited to launch her new business, candidate-first.com, focused on delivering quality candidate responses. Connect with Caroline LinkedIn: https://www.linkedin.com/in/carolinevermeulen1/ Website: www.candidate-first.com About Me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.…

1
How and When to Ask Intelligent Interview Questions 23:45

vor 12 weeks23:45

23:45

In this episode, I talk about the importance of asking intelligent questions during job interviews. I share insights from my experience coaching candidates, emphasizing how well-structured questions can show enthusiasm, knowledge, and fitness for the role. I cover the types of questions to ask, how to structure them effectively, and the timing to maximize impact. I also discuss the importance of understanding the hiring manager's needs and building rapport throughout the interview process. Here's what you're in for: How to ask intelligent questions in an interview? What are the types of questions can you focus on? Which stages of the interview is the best time to ask the questions? Timestamps: 01:51 Interview Strategies 03:25 The Situation 06:39 The Three Main Topics of the Questions 10:13 Examples of Questions to Ask 11:09 How to Ask Iintelligent Questions 21:25 Summary About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/…

1
Troels Jordansen, Executive Chairman of Keli Therapeutics, in Cell Therapy and Biotech Recession Talks 33:00

vor 13 weeks33:00

33:00

In this episode, I talked with Troels Jordansen, chairman at KELI Therapeutics, where he discusses the ongoing recession in the biotech industry. He shares insights from the Advanced Therapies Congress in Lisbon, highlighting investor optimism and the importance of smart hiring and team building in biotech companies. Troels shares valuable lessons learned from past experiences, including the need for companies to secure sufficient funding and the significance of having the right people in key positions. The discussion also covers Troels' interest in the hair care market, highlighting its increasing connection with biotech. Here's what you're in: What do people forget during the good times? Why this recession is not the worst? What are the big mistakes companies are still making? Timestamps: 02:17 Introduction and Career Background 07:43 Biotech Recession and Insights from the Advanced Therapies Congress 12:46 Strategies on Reaching Out to Investors 18:13 The Challenges of Being in a Hiring Position 21:16 Finding the Right People for the Team 25:50 Lessons from Past and the Current State of the Biotech Inddustry 28:36 Exploring the Hair Care Market About Troels Troels Jordansen is the Executive Chairman at KELI Therapeutics, a stem cell and gene therapy company based in Lithuania, with nearly 30 years of experience in international healthcare of which about 25 years focusing on tissue engineering and cellular therapies. Though not a scientist, his commercial expertise has led him to roles in pioneering companies like Genzyme and Isotis, where he contributed to major innovations and IPOs. Troels has a marketing and management background earned from Copenhagen Business School and Aarhus Business College. Connect with Troels LinkedIn: https://www.linkedin.com/in/troelsjordansen/ Website: https://keli.eu/ About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.…

1
Negotiation Strategies and Insights from Harvard Course ft. Sophie He, Head of M&A and Partnering at Bracco 35:22

vor 14 weeks35:22

35:22

In this episode, I talked with Sophie, a leader at the Italian pharmaceutical company Bracco, about her experiences and learnings at the Harvard’s negotiation course. Sophie shares her experiences attending the course, highlighting the immersive nature of the program and the diverse backgrounds of participants. We discuss her key takeaways from the course, including the importance of gathering information and maximizing value in negotiations. The podcast also covers practical strategies for negotiating salaries and promotions, emphasizing the importance of understanding one's value and the company's perspective. Here's what you're in: Where do people go wrong in negotiation? Is Trump a good negotiator? How could the Harvard Negotiation Course benefit people working in clinical research? Timestamps: 01:41 Introduction to Bracco and Career Background 04:40 The Harvard Negotiation Course Experience - What's in it? 12:26 Key Takeaways from the Course 18:29 The Qualities of a Good Negotiator 20:42 How Good Negotiators Do Negotiation 26:44 Negotiating Better Salaries and Promotions 30:15 Final Thoughts on Negotiation About Sophie Sophie He is the Head of M&A and Partnering at Bracco, the globally leading players in diagnostic pharmaceuticals. She has over a decade of experience in the pharmaceutical industry. She has been heavily involved in M&A and business development, which goes with her passion of negotiation. Prior to her roles in pharma, she gained experience in consulting and banking. She holds a PhD from MIT and NUS (National Univeristy of Singapore), has recently attended a Harvard Course, and is a CFA holder. Connect with Sophie LinkedIn: https://www.linkedin.com/in/sophie-he-phd/ Website: https://www.bracco.com/ Harvard Course Link: https://www.exed.hbs.edu/changing-game-negotiation-competitive-decision-making About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.…

1
The 3 Interview Questions You Must Succeed In 16:36

vor 15 weeks16:36

16:36

In this episode, I talked about a simple yet effective way to ace your interviews by focusing on the three main questions: 'Who are you?', 'Why are you applying?', and 'Why are you looking to leave?'. Learn how to answer these questions in under 2 minutes, how to successfully move on with these three questions, give relevant ABC story, what kind of answers to avoid, and strategy on how to control the conversation. This will be helpful for those who wanted to significantly improve and do well in all of their interviews. Here's what you're in for: Why are the three core interview questions that will make you one step ahead in interviews? Why is it important to understand the hiring manager's perspective? Timestamps: 00:36 The Three Main Interview Questions 01:35 One Fatal Mistake During An Interview 02:58 Answering The 3 Questions 03:52 Controlling The Narrative 06:12 Going One Step Ahead In Your Interview 08:04 Avoiding Giving Subjective Answers 10:05 Moving On With The Interview 13:49 Final Summary 14:38 Conclusion and Final Thoughts About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/ Opinions and comments expressed by the guest do not represent the company and are fully their own.…

1
Nikolaus Trede, SVP Clinical Development in Century Therapeutics - Lessons from Breyanzi and Global Cell Therapy Trials 39:08

vor 16 weeks39:08

39:08

In this episode, I interview Nikolaus Trede, the SVP Clinical Development in Century Therapeutics, an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform. He shares his journey from academia to industry, offering unique experience into the ever-changing world of cell therapies. We also discuss: The impact of ready-made therapies on cancer treatment Common problems in clinical trials and how to dodge them What we can learn from the ROCKET trial's close call Tips for assembling a top-notch biotech team Turning obstacles into major advances in medical research Here's what you're in: 02:15 Meeting Nik and his background 04:30 The promise of new cell therapies 09:45 Tough parts of creating new treatments 15:20 How to build strong teams 21:35 What we learned from the ROCKET trial 27:10 Success stories of Lysocell and reaching more patients 32:55 How to talk better in medical research 38:40 Making a good team spirit at work 43:15 Why getting along matters in teams 46:30 Final thoughts and advice for newcomers About Nikolaus Trede Nikolaus Trede is a physician-scientist specializing in immunology and pediatric hematology/oncology. With a PhD in immunology and 15 years of clinical experience at institutions like Harvard Medical School and the University of Utah, he bridges basic science and patient care. Dr. Trede has led academic research labs and industry teams, designing and supervising clinical trials for innovative cancer treatments. His work spans from chronic myelogenous leukemia studies to current CAR T cell trials in hematologic malignancies at JUNO/Celgene, demonstrating his expertise in translating scientific concepts into clinical applications. Connect with Nikolaus Trede: LinkedIn: https://www.linkedin.com/in/nikolaus-trede/ Website: https://www.centurytx.com/ About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/…

1
Re-Entering the Workforce and Career Growth in Regulatory Affairs with Mary Christian 50:45

vor 25 weeks50:45

50:45

How do you balance a career in regulatory affairs with family life? In this episode, Charles discusses this topic with Mary Christian, the Senior Vice President of Regulatory and Safety at C4 Therapeutics, a biopharmaceutical company focused on targeted protein degradation. They talk about the importance of effective communication, career development, and work-life balance in the pharmaceutical industry. Mary also offers advice for young mothers and career professionals on making choices that align with their personal and professional goals, highlighting the evolving nature of career and family life. Here's what you're in: 00:02 Introduction and Career Background 07:52 Building Capabilities for Career Reentry 16:42 C4 Therapeutics and Protein Degradation 24:00 Communication in Clinical Trials 28:35 Overcoming Challenges in Decision-Making 35:47 Shifting Perspectives in Career Growth 42:01 Balancing Career and Family Life About Mary Christian Mary Christian, PharmD, MBA, is the Senior Vice President of Regulatory and Safety at C4 Therapeutics, Inc. A passionate and decisive biopharma executive, leader, and advisor, Mary delivers visionary solutions across all phases of drug development. She has demonstrated success in creating, building, and integrating novel capabilities in an international biopharma environment, as well as deconstructing organizations to create fit-for-purpose solutions and value opportunities. Apart from her work, Mary is devoted to mentoring through initiatives like Project Onramp. She has also steered many company changes. On top of her career, she's a proud mom to three accomplished adults and a loving grandmother to four girls. Connect with Mary: LinkedIn: https://www.linkedin.com/in/mary-christianpharmd Website: https://c4therapeutics.com/ About Charles Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry. He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate. In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with Charles: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/…

1
From Neuroscientist to Biotech Innovator ft.Anita Scheuber 43:42

vor 26 weeks43:42

43:42

Leadership and Diversity in Drug Development with Anita Scheuber. In this episode, Charles talks with Anita Scheuber,the SVP of clinical development at Nimbus Therapeutics—a biotech firm using computational technology to develop medicines. She shares their pioneering work in AI-targeted drug discovery and her experience co-founding the biotech startup Hestia. Anita highlights how different backgrounds help solve problems, the value of mentorship, and how to beat feelings of being an imposter. She also shares tips for strong leadership and gives guidance to budding biotech entrepreneurs. Here's what you're in: 01:01 Anita's Journey to the U.S. 02:35 Switching from Neuroscience to Oncology 07:56 Joining Nimbus Therapeutics 10:07 Why Workplace Diversity Matters 14:56 Founding Hestia-A Startup biotech 24:40 Leadership and Personal Growth 30:14 Advice for Aspiring Entrepreneurs 32:16 Final Thoughts and Conclusion About Anita Scheuber Anita Scheuber brings over 15 years of pharmaceutical industry experience to Nimbus, specializing in oncology clinical development. Her expertise spans small molecule and immuno-oncology drug development across various stages and tumor types. She has held leadership positions at Trillium Therapeutics, Boston Pharmaceuticals, Pfizer, and GSK. She holds an M.D. from the University of Zurich and a Ph.D. in Neurosciences from Sorbonne University, with additional training at Harvard Medical School and Swiss hospitals. Connect with Guest LinkedIn: https://www.linkedin.com/in/anita-scheuber-8a1a8220/ Website: https://www.nimbustx.com/ About Charles Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry. He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate. In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with Charles: LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/ Website: https://www.discera-search.com/…

TERRO T300B Liquid Ant Killer, 12 Bait Stations

Tubi: Watch Free Movies & TV Shows

Minecraft

Podcasts, die es wert sind, gehört zu werden

A Dose of Reality with Charles Spence

A Dose of Reality with Charles Spence

Podcasts, die es wert sind, gehört zu werden

Willkommen auf Player FM!

Amazon eGift Card - Amazon Logo (Animated)

TurboTax Home & Business 2024 Tax Software, Federal & State Tax Return [PC/MAC Download]

Iron Flame (The Empyrean Book 2)

Plex: Stream Movies & TV

Kurzanleitung